Corneal degeneration is more common in white women

Article

Peripheral hypertrophic subepithelial corneal degeneration is an uncommon disorder that occurs mostly in white women with a distinct phenotype, claims a study in the journal Ophthalmology.

Peripheral hypertrophic subepithelial corneal degeneration is an uncommon disorder that occurs mostly in white women with a distinct phenotype, claims a study in the journal Ophthalmology.

The retrospective case series, led by Dr Daniel M. Gore, Moorfields Eye Hospital NHS Foundation Trust, London, UK, involved 22 patients under care of the External Disease Service at the hospital. The main outcome measures were clinical phenotype, symptoms, recurrence rate after surgery and histopathologic results.

Of the patients studied, 91% had peripheral and bilateral disorders and 41% had elevated circumferential peripheral subepithelial corneal opacities and adjacent abnormal limbal vasculature, with or without pseudopterygia. Seven patients from the latter group had bilateral disease.

The symptoms included ocular surface discomfort in 45% of patients, reduced vision in 18% of patients and both symptoms present in 23% of patients. It was discovered that 14% of patients were asymptomatic, 36% were administered topical lubricants, one patient required spectacles and 32% of patients underwent superficial keratectomy. The histopathologic changes were similar to those found in pterygia and Salzmann’s nodular degeneration.

Surgical excision was performed in 30% of the patients with infrequent short-term recurrences. The cause of peripheral hypertrophic subepithelial corneal degeneration is still unknown.

The paper can be viewed here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.